Opus Genetics Enters Material Definitive Agreement
Ticker: IRD · Form: 8-K · Filed: Jul 23, 2025 · CIK: 1228627
Sentiment: neutral
Topics: material-definitive-agreement, financial-statements, exhibits
TL;DR
Opus Genetics signed a new deal, filing includes financials & exhibits.
AI Summary
On July 22, 2025, Opus Genetics, Inc. entered into a material definitive agreement. The filing also includes information regarding Regulation FD disclosure and financial statements and exhibits. The company was formerly known as Ocuphire Pharma, Inc. and Rexahn Pharmaceuticals, Inc.
Why It Matters
This filing indicates a significant new agreement for Opus Genetics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the nature of this agreement is not detailed in the provided excerpt.
Key Players & Entities
- Opus Genetics, Inc. (company) — Registrant
- Ocuphire Pharma, Inc. (company) — Former name
- Rexahn Pharmaceuticals, Inc. (company) — Former name
- July 22, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Opus Genetics, Inc. on July 22, 2025?
The provided excerpt does not specify the details of the material definitive agreement.
What are the key financial highlights or figures reported in this 8-K filing?
The excerpt mentions 'Financial Statements and Exhibits' but does not provide specific financial numbers.
What was Opus Genetics, Inc. previously known as?
Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and Rexahn Pharmaceuticals, Inc.
What is the principal executive office address for Opus Genetics, Inc.?
The principal executive offices are located at 8 Davis Drive, Suite 220, Durham, NC 27713.
What is the filing date for this 8-K report?
The filing date for this 8-K report is July 23, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 23, 2025 regarding Opus Genetics, Inc. (IRD).